Bruker Spatial Biology to Announce Groundbreaking Advances at AGBT 2025
Bruker (BRKR) announced major advancements in spatial biology to be unveiled at AGBT 2025, including four key innovations: CosMx Whole Transcriptome Panel (WTX), capable of detecting over 18,000 RNA transcripts at single-cell resolution; expansion of GeoMx protein panel to 1,000-plex capability; launch of PaintScape, a platform for 3D genome visualization; and enhanced CellScape PowerOMX software engine for spatial proteomics.
The WTX assay will begin taking orders in April with summer shipments, while a Mouse version is expected later in 2025. The expanded GeoMx 1K Panel is scheduled for summer release. The company also announced the Sapphire Spatial Program, offering premium services for CosMx SMI users, and extended collaboration with Weill Cornell Medicine on the Spatial Atlas of Human Anatomy (SAHA) initiative to map 30 non-diseased organs.
Bruker (BRKR) ha annunciato importanti progressi nella biologia spaziale che saranno svelati all'AGBT 2025, comprese quattro innovazioni chiave: CosMx Whole Transcriptome Panel (WTX), in grado di rilevare oltre 18.000 trascritti di RNA a risoluzione di singola cellula; espansione del GeoMx protein panel a capacità 1.000-plex; lancio di PaintScape, una piattaforma per la visualizzazione del genoma in 3D; e un motore software potenziato CellScape PowerOMX per la proteomica spaziale.
Il saggio WTX inizierà a ricevere ordini ad aprile con spedizioni estive, mentre una versione per topi è prevista per la fine del 2025. Il pannello GeoMx 1K espanso è programmato per il rilascio estivo. L'azienda ha anche annunciato il Sapphire Spatial Program, che offre servizi premium per gli utenti di CosMx SMI, e una collaborazione estesa con il Weill Cornell Medicine sull'iniziativa Spatial Atlas of Human Anatomy (SAHA) per mappare 30 organi non malati.
Bruker (BRKR) anunció importantes avances en biología espacial que se revelarán en AGBT 2025, incluyendo cuatro innovaciones clave: CosMx Whole Transcriptome Panel (WTX), capaz de detectar más de 18,000 transcritos de ARN a resolución de una sola célula; expansión del GeoMx protein panel a capacidad de 1,000-plex; lanzamiento de PaintScape, una plataforma para la visualización del genoma en 3D; y un motor de software mejorado CellScape PowerOMX para proteómica espacial.
El ensayo WTX comenzará a recibir pedidos en abril con envíos programados para el verano, mientras que se espera una versión para ratones para finales de 2025. El panel GeoMx 1K expandido está programado para su lanzamiento en verano. La compañía también anunció el Sapphire Spatial Program, que ofrece servicios premium para los usuarios de CosMx SMI, y una colaboración ampliada con Weill Cornell Medicine en la iniciativa Spatial Atlas of Human Anatomy (SAHA) para mapear 30 órganos no enfermos.
브루커 (BRKR)는 AGBT 2025에서 공개될 공간 생물학의 주요 발전을 발표했으며, 네 가지 주요 혁신을 포함합니다: CosMx Whole Transcriptome Panel (WTX), 단일 세포 해상도로 18,000개 이상의 RNA 전사체를 감지할 수 있는 능력; GeoMx 단백질 패널의 1,000-plex 기능 확장; 3D 유전체 시각화를 위한 플랫폼인 PaintScape 출시; 그리고 공간 단백질체학을 위한 향상된 CellScape PowerOMX 소프트웨어 엔진.
WTX 분석은 4월부터 주문을 받기 시작하며 여름에 배송될 예정이며, 쥐 버전은 2025년 후반에 출시될 것으로 예상됩니다. 확장된 GeoMx 1K 패널은 여름 출시가 예정되어 있습니다. 회사는 또한 CosMx SMI 사용자에게 프리미엄 서비스를 제공하는 Sapphire Spatial Program을 발표했으며, 30개의 비질병 장기를 매핑하기 위한 Spatial Atlas of Human Anatomy (SAHA) 이니셔티브에 대해 Weill Cornell Medicine과의 협력을 연장했습니다.
Bruker (BRKR) a annoncé des avancées majeures en biologie spatiale qui seront dévoilées à l'AGBT 2025, y compris quatre innovations clés : CosMx Whole Transcriptome Panel (WTX), capable de détecter plus de 18 000 transcrits d'ARN à une résolution de cellule unique ; expansion du GeoMx protein panel à une capacité de 1 000 plex ; lancement de PaintScape, une plateforme pour la visualisation du génome en 3D ; et un moteur logiciel amélioré CellScape PowerOMX pour la protéomique spatiale.
Le test WTX commencera à prendre des commandes en avril avec des expéditions prévues pour l'été, tandis qu'une version pour souris est attendue plus tard en 2025. Le panneau GeoMx 1K élargi est prévu pour une sortie estivale. L'entreprise a également annoncé le Sapphire Spatial Program, offrant des services premium pour les utilisateurs de CosMx SMI, ainsi qu'une collaboration étendue avec Weill Cornell Medicine dans le cadre de l'initiative Spatial Atlas of Human Anatomy (SAHA) pour cartographier 30 organes non malades.
Bruker (BRKR) hat bedeutende Fortschritte in der räumlichen Biologie angekündigt, die auf der AGBT 2025 vorgestellt werden, einschließlich vier wichtiger Innovationen: CosMx Whole Transcriptome Panel (WTX), das in der Lage ist, über 18.000 RNA-Transkripte mit Einzelzellauflösung zu erkennen; Erweiterung des GeoMx Proteinpanels auf 1.000-plex-Funktionalität; Einführung von PaintScape, einer Plattform zur 3D-Visualisierung des Genoms; und eine verbesserte CellScape PowerOMX Software-Engine für die räumliche Proteomik.
Der WTX-Test wird im April Bestellungen entgegennehmen, mit Versand im Sommer, während eine Mausversion später im Jahr 2025 erwartet wird. Das erweiterte GeoMx 1K-Panel ist für die Sommerveröffentlichung geplant. Das Unternehmen kündigte auch das Sapphire Spatial Program an, das Premium-Dienste für CosMx SMI-Nutzer anbietet, sowie eine erweiterte Zusammenarbeit mit dem Weill Cornell Medicine im Rahmen der Spatial Atlas of Human Anatomy (SAHA)-Initiative zur Kartierung von 30 nicht erkrankten Organen.
- Launch of CosMx WTX panel enabling detection of 18,000+ RNA transcripts
- Expansion of GeoMx protein panel to 1000-plex capability
- Introduction of new PaintScape platform for 3D genome visualization
- Enhancement of CellScape platform with PowerOMX Engine for improved throughput
- None.
Insights
The simultaneous announcement of four major spatial biology innovations signals Bruker's aggressive push to dominate the rapidly growing spatial biology market, estimated to reach
- The CosMx WTX panel's ability to analyze 18,000+ RNA transcripts while maintaining spatial context represents a significant competitive advantage over traditional single-cell sequencing methods. This capability addresses a critical market need for comprehensive spatial transcriptomics, particularly valuable in oncology and neuroscience research.
- The expansion of GeoMx to 1000-plex protein profiling sets a new industry benchmark, potentially capturing market share from competitors to lower-plex capabilities. This advancement enables researchers to simultaneously analyze both proteome and transcriptome data from the same tissue section, a capability that could accelerate biomarker discovery and drug development processes.
- The introduction of PaintScape for 3D genome visualization opens an entirely new market segment, potentially creating first-mover advantages in structural genomics research.
The timing of these launches, scheduled for commercial availability in summer 2025, appears strategically coordinated to maximize market impact. The enhanced customer support programs, including the Sapphire Spatial Program and Galaxy Spatial Tour, demonstrate a sophisticated go-to-market strategy that could accelerate adoption rates and strengthen customer loyalty.
The collaboration with Weill Cornell Medicine on the Spatial Atlas of Human Anatomy initiative provides valuable validation and could generate significant reference data, potentially establishing Bruker's platforms as industry standards. This comprehensive approach to spatial biology, combining cutting-edge technology with strong support infrastructure, positions Bruker to capture a larger share of the spatial biology market and potentially accelerate revenue growth in their life sciences segment.
Advancements to include CosMx® Whole Transcriptome Panel; enhanced technology engine to power CellScape™ for spatial proteomics; expansion to 1000-plex protein assay on GeoMx® DSP; and launch of PaintScape™, a revolutionary platform enabling direct visualization of the 3D genome
RNA transcripts in human hippocampus FFPE tissue assayed with the CosMx Whole Transcriptome Panel (Photo: Business Wire)
- the first and only Whole Transcriptome Panel (WTX) on the subcellular resolution CosMx Spatial Molecular Imager (SMI) platform,
- the new PaintScape platform for direct visualization of the 3D genome,
- the new CellScape PowerOMX™ software engine, developed to optimize the performance of the new EpicIF technology on the CellScape spatial proteomics platform,
- a doubling of the GeoMx protein panel to an unprecedented 1,000 plex for the highest level of tissue multiomics
CosMx Whole Transcriptome Panel (WTX) Enables Deeper Insights into Biological Mechanisms
The Whole Transcriptome Panel for Bruker’s CosMx Spatial Molecular Imager (SMI) represents a breakthrough in spatial biology. With the ability to detect and quantify over 18,000 RNA transcripts at single-cell and subcellular resolution, the WTX assay enables comprehensive spatial transcriptomics. The intricate molecular heterogeneity of tissues can be explored with unprecedented detail, unlocking deeper discoveries in oncology, neuroscience, immunology, and developmental biology.
“The WTX assay produces data on par with traditional single cell RNA sequencing in terms of genomic breadth, while preserving spatial single cell resolution — this unlocks a tremendous opportunity for discovery and validation of biology,” said Parambir Dulai, M.D., Associate Professor of Medicine at Northwestern University, who applied the CosMx WTX assay in an early access program.
“The CosMx Whole Transcriptome Panel represents a significant leap forward for spatial biology accelerating discoveries in translational research and precision medicine,” said Joe Beechem, Ph.D., Chief Scientific Officer at Bruker Spatial Biology. “Researchers can now analyze the expression of the entire protein-coding transcriptome from every cell in their sample, while preserving the spatial relationships of the cells at sub-cellular resolution. This enables a more comprehensive understanding of pathways and interactions for uncovering novel biological mechanisms. We believe the WTX assay will be the primary choice for single cell analysis on fresh frozen or FFPE tissue samples for advanced applications that are currently limited to single cell RNA-seq.”
Orders for the CosMx Human Whole Transcriptome Panel will commence in April with commercial shipments expected this summer. A Mouse Whole Transcriptome Panel is expected to launch later in 2025.
GeoMx to Offer High Plex Spatial Multiomics
On the GeoMx DSP platform, Bruker announces an expanded protein panel to spatially profile 1000 proteins in addition to the entire transcriptome. This marks a significant evolution of GeoMx into a powerful multiomic platform with the capability of simultaneous, same-section, multiomic analysis of the whole transcriptome and 1000 proteins. Taking the already uniquely unprecedented multiomic plex levels to even higher levels, further differentiating the meaning of multiomic, will enable an even more complete picture of complex biological pathways. The 1K Panel on the GeoMx is expected to ship this summer.
Unlocking the 3D Genome with PaintScape
Bruker’s new PaintScape platform opens a new frontier in the field of spatial biology. Leveraging unique jebFISH™ technology, PaintScape enables researchers to perform multiplexed, direct visualization of genome architecture and chromosomal structure in individual single cells with ultra-high spatial resolution. By providing a detailed view of the 3D genome, PaintScape empowers researchers to understand how genome structural variations impact gene expression and their implication in the mechanisms of disease.
"The introduction of PaintScape marks a new milestone in the history spatial biology," said Mark R. Munch, Ph.D., President of the Bruker Nano Group. "With PaintScape, we now offer researchers the unique and unprecedented ability to elucidate aspects of dysregulation of cellular programs leading to changes in gene expression. PaintScape is opening a new window in fundamental and medical discovery science."
CellScape with New Software Engine to Improve Throughput and Data Quality
Bruker announces enhancements to its CellScape platform for spatial proteomics with the PowerOMX™ Engine. PowerOMX is the data engine powering CellScape’s EpicIF technology and seamlessly feeds data to the recently launched CellScape Navigator GUI. PowerOMX includes streamlined data acquisition, processing, and reconstruction workflows resulting in improved throughput, image processing, and data integrity. CellScape instruments with PowerOMX will begin shipping immediately, and installed instruments will be eligible for upgrades.
“Building on the recently launched improvements to the CellScape platform, including the transformational EpicIF technology and CellScape Navigator software, PowerOMX represents another big step forward on this spatial proteomics platform,” said Oliver Braubach, Ph.D., Director of R&D for Bruker Spatial Biology. “With PowerOMX, researchers can harness the full potential of the EpicIF technology with faster data acquisition and processing, and best-in-class data reconstruction and image processing.”
Enhanced Customer Support Programs and Collaborations to Accelerate Productivity with New Spatial Biology Technologies
Bruker additionally plans to announce the launch of the Sapphire Spatial Program, a new premium suite of services designed to provide an unparalleled customer experience for advanced, high-throughput CosMx SMI users. Customers will have access to a dedicated concierge, performance monitoring tools with personalized guidance from spatial experts, and advanced post-run analytics. The program is in its pilot stage with a broader expansion planned for later this year.
Bruker Spatial Biology also plans to announce the extension of their collaboration with Weill Cornell Medicine on the Spatial Atlas of Human Anatomy (SAHA) initiative, to create multicellular, single-cell, and sub-cellular maps of 30 non-diseased organs from a healthy and diverse population of adults. “High-resolution spatial data sets from SAHA are re-defining how we see human cells, tissues, and interactions. I look forward to continuing this work and making these data publicly available,” said Chris Mason, Ph.D., Professor of Physiology and Biophysics at Weill Cornell Medicine.
Dr. Mason, who previously served on NanoString’s Scientific Advisory Board before the company’s acquisition by Bruker, has no financial interest in Bruker.
Additionally, Bruker Spatial Biology will be launching an educational best practice sharing workshop starting in March named the “Galaxy Spatial Tour.” Scheduled worldwide, Galaxy Spatial Tour events will provide an opportunity for customers to directly connect with Bruker’s spatial biology experts.
Join Bruker at AGBT 2025
Bruker will share more details on these innovations at the AGBT General Meeting in their hospitality suite Osprey 10 and in a workshop “Expanding the Limits of Spatial Biology: Comprehensive Integrated Technologies for Spatial Multiomics”, on February 26, 2025, at 12:15 PM EST. Demonstrations of the entire suite of Bruker Spatial Biology platforms including CosMx and WTX, GeoMx, CellScape, and PaintScape will showcase the transformative potential of these spatial biology technologies.
For more information about Bruker Spatial Biology and its innovations, please visit www.brukerspatialbiology.com.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is at the forefront of the post-genomic era, helping scientists and engineers make groundbreaking discoveries that enhance human life. Our high-performance instruments and analytical solutions enable the exploration of life and materials at the molecular, cellular, and microscopic levels. Working closely with customers, we drive innovation, boost productivity, and support success in life sciences, biopharma, microscopy, nanoanalysis, industrial research, and next-gen semiconductor metrology for AI. Bruker provides highly differentiated, cutting-edge systems for preclinical imaging, clinical phenomics, proteomics, multiomics, spatial and single-cell biology, functional structural biology, clinical microbiology, and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250221715537/en/
Media Contact:
Kevin Gamber
Vice President, Marketing
Bruker Spatial Biology
T: +1-650-314-1456
E: kevin.gamber@bruker.com
Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1-978-313-5800
E: Investor.Relations@bruker.com
Source: Bruker Corporation
FAQ
When will Bruker (BRKR) start shipping the CosMx Whole Transcriptome Panel?
What is the capability of Bruker's new GeoMx protein panel expansion?
What is the purpose of Bruker's new PaintScape platform?
What improvements does the PowerOMX Engine bring to Bruker's CellScape platform?
What is Bruker's Sapphire Spatial Program?
